A Phase II Trial to Assess the Activity of MVA 5T4 (Trovax) Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate Cancer (HRPC)
Latest Information Update: 10 Nov 2021
Price :
$35 *
At a glance
- Drugs MVA 5T4 (Primary) ; Docetaxel
- Indications Prostate cancer
- Focus Adverse reactions
- 05 Sep 2007 New trial record.